| Market Cap | 11.55M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.42M | Forward P/E | 3.72 | EPS next Y | - | 50D Avg Chg | -14.00% |
| Sales | 8.26M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -39.00% |
| Dividend | N/A | Price/Book | 0.49 | EPS next 5Y | 15.00% | 52W High Chg | -75.00% |
| Recommedations | 2.00 | Quick Ratio | 19.16 | Shares Outstanding | 7.76M | 52W Low Chg | 12.00% |
| Insider Own | 1.41% | ROA | -11.96% | Shares Float | 7.57M | Beta | 2.31 |
| Inst Own | 8.86% | ROE | -18.97% | Shares Shorted/Prior | 40.90K/112.80K | Price | 1.49 |
| Gross Margin | 69.65% | Profit Margin | -53.50% | Avg. Volume | 52,493 | Target Price | - |
| Oper. Margin | -57.43% | Earnings Date | Apr 24 | Volume | 3,649 | Change | -0.75% |
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
| Rodman & Renshaw | Buy | Nov 25, 20 |